Nogapendekin Alfa Inbakicept-Pmln: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Nogapendekin Alfa Inbakicept-Pmln. Educational only — not medical advice.
Labeled uses
ANKTIVA in combination with Bacillus Calmette-Guérin (BCG) is indicated for the treatment of adult patients with BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.
Source: FDA labeling via NIH DailyMed (set eae31db8…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.